About Biogen Inc.
https://www.biogen.comBiogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
CEO
Christopher A. Viehbacher
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2001-01-18 | Forward | 3:1 |
| 1999-12-21 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 746
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Stifel
Buy
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
Truist Securities
Buy
Goldman Sachs
Buy
RBC Capital
Outperform
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:17.29M
Value:$2.93B
PRIMECAP MANAGEMENT CO/CA/
Shares:14.95M
Value:$2.53B
BLACKROCK, INC.
Shares:14.76M
Value:$2.5B
Summary
Showing Top 3 of 1,335
About Biogen Inc.
https://www.biogen.comBiogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $2.45B ▼ | $964.4M ▼ | $466.5M ▼ | 19% ▼ | $3.18 ▼ | $826.9M ▼ |
| Q2-2025 | $2.65B ▲ | $1.11B ▼ | $634.8M ▲ | 24% ▲ | $4.35 ▲ | $1.11B ▲ |
| Q1-2025 | $2.43B ▼ | $1.12B ▼ | $240.5M ▼ | 9.89% ▼ | $1.65 ▼ | $865.1M ▲ |
| Q4-2024 | $2.45B ▼ | $1.36B ▲ | $266.7M ▼ | 10.86% ▼ | $1.83 ▼ | $691.7M ▼ |
| Q3-2024 | $2.47B | $1.25B | $388.5M | 15.76% | $2.67 | $714.4M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $3.96B ▲ | $29.21B ▲ | $11B ▲ | $18.21B ▲ |
| Q2-2025 | $2.76B ▲ | $28.33B ▲ | $10.7B ▼ | $17.63B ▲ |
| Q1-2025 | $2.6B ▲ | $28.03B ▼ | $11.05B ▼ | $16.98B ▲ |
| Q4-2024 | $2.38B ▲ | $28.05B ▼ | $11.33B ▼ | $16.72B ▲ |
| Q3-2024 | $1.7B | $28.31B | $11.95B | $16.36B |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $466.5M ▼ | $1.27B ▲ | $-35.1M ▲ | $-130.2M ▼ | $1.1B ▲ | $1.23B ▲ |
| Q2-2025 | $634.8M ▲ | $160.9M ▼ | $-57M ▼ | $-11.7M ▲ | $160.5M ▼ | $144.3M ▼ |
| Q1-2025 | $240.5M ▼ | $259.3M ▼ | $-47.3M ▼ | $-23M ▼ | $223.3M ▼ | $212.2M ▼ |
| Q4-2024 | $266.7M ▼ | $760.9M ▼ | $-18.6M ▲ | $7.9M ▲ | $675.8M ▲ | $694.6M ▼ |
| Q3-2024 | $388.5M | $935.6M | $-1.18B | $-6.6M | $-209.7M | $805.6M |
Revenue by Products
| Product | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 Fumarate | $400.00M ▲ | $340.00M ▼ | $410.00M ▲ | $380.00M ▼ |
 Interferon | $240.00M ▲ | $230.00M ▼ | $250.00M ▲ | $250.00M ▲ |
 MS Product Revenues | $1.07Bn ▲ | $950.00M ▼ | $1.11Bn ▲ | $1.06Bn ▼ |
 SPINRAZA | $420.00M ▲ | $420.00M ▲ | $390.00M ▼ | $370.00M ▼ |
 TYSABRI product | $420.00M ▲ | $380.00M ▼ | $450.00M ▲ | $430.00M ▼ |
Revenue by Geography
| Region | Q4-2024 | Q1-2025 | Q2-2025 | Q3-2025 |
|---|---|---|---|---|
 NonUS | $1.00Bn ▲ | $970.00M ▼ | $940.00M ▼ | $910.00M ▼ |
 UNITED STATES | $830.00M ▲ | $750.00M ▼ | $940.00M ▲ | $940.00M ▲ |
CEO
Christopher A. Viehbacher
Compensation Summary
(Year 2024)
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2001-01-18 | Forward | 3:1 |
| 1999-12-21 | Forward | 2:1 |
ETFs Holding This Stock
Summary
Showing Top 3 of 746
Ratings Snapshot
Rating : A-
Most Recent Analyst Grades
Stifel
Buy
HC Wainwright & Co.
Buy
Canaccord Genuity
Buy
Truist Securities
Buy
Goldman Sachs
Buy
RBC Capital
Outperform
Grade Summary
Showing Top 6 of 20
Price Target
Institutional Ownership
VANGUARD GROUP INC
Shares:17.29M
Value:$2.93B
PRIMECAP MANAGEMENT CO/CA/
Shares:14.95M
Value:$2.53B
BLACKROCK, INC.
Shares:14.76M
Value:$2.5B
Summary
Showing Top 3 of 1,335